Taxanes and anthracyclines in early breast cancer: which first?

The Lancet Oncology

Volumn 11, Issue 3, 2010, Pages 219-220

  Wildiers, Hans ^a   Forceville, Kathleen ^a   Paridaens, Robert ^a   Joensuu, Heikki ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST ADENOCARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; EARLY CANCER; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SKIN TOXICITY;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; TAXOIDS;

EID: 77349117046     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70025-5     Document Type: Letter

References (11)

1. Simon R., and Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 3 (2006) 406-407
2. Puhalla S., Mrozek E., Young D., et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol 26 (2008) 1691-1697
3. Wildiers H., Dirix L., Neven P., et al. Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat 114 (2009) 103-112
4. Piedbois P., Serin D., Priou F., et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 18 (2007) 52-57
5. Cardoso F., Ferreira A.F., Crown J., et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. Anticancer Res 21 (2001) 789-795
6. Earl H.M., Vallier A., Hiller L., et al. Neo-Tango: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel +/- gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). Proc Am Soc Clin Oncol 27 suppl (2009) abstr 522.
7. Miller K.D., Soule S.E., Calley C., et al. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 89 (2005) 187-197
8. Cousin S., Mailliez A., Servent V., et al. Feasibility of the sequential FEC 100-taxotere chemotherapy regimen as an adjuvant or neoadjuvant treatment for breast cancer. Experience of a single institution. Cancer Res 69 suppl (2009) abstr 4110.
9. Polyzos A., Malamos N., Boukovinas I., et al. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 119 (2010) 95-104
10. Joensuu H., Bono P., Kataja V., et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol 27 (2009) 5685-5692
11. Guo B.Q., Villeneuve D.J., Hembruff S.L., et al. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 85 (2004) 31-51